China Life Sciences Newsletter -- April 2012

more+
less-
more+
less-
Explore:  China Life Sciences USPTO

In This Issue:

*Investor Q&A

*Trends and Best Practices in R&D Strategic Partnerships in China

*USPTO Proposed Rules on Preissuance Submissions

Excerpt from Investor Q&A

Interview by Chuck Comey, Dave Chang, and Patrick Fischer

John Oyler is the founder and CEO of BeiGene Ltd., a Beijing-based biotechnology company that focuses on discovering and developing innovative oncology drugs. Few can match Mr. Oyler’s record as a serial founder. He previously founded and was CEO of BioDuro, a 700-person integrated contract research organization (CRO) in Beijing, which was sold to PPD with attractive returns. Mr. Oyler is also the former CEO of Galenea, a Bostonbased biotech spinout from Massachusetts Institute of Technology with funding from Otsuka; the former co-CEO of Genta, a publicly traded oncology company that grew to be worth $1.7 billion; and the former founder and president of Telephia, which was bought by Nielsen. He holds an MBA from Stanford University and a BS from Massachusetts Institute of Technology.

Please see full newsletter below for more information.

LOADING PDF: If there are any problems, click here to download the file.

Topics:  China, Life Sciences, USPTO

Published In: Administrative Agency Updates, Business Organization Updates, Intellectual Property Updates, International Trade Updates, Science, Computers & Technology Updates

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Morrison & Foerster LLP | Attorney Advertising

Don't miss a thing! Build a custom news brief:

Read fresh new writing on compliance, cybersecurity, Dodd-Frank, whistleblowers, social media, hiring & firing, patent reform, the NLRB, Obamacare, the SEC…

…or whatever matters the most to you. Follow authors, firms, and topics on JD Supra.

Create your news brief now - it's free and easy »